Last reviewed · How we verify

Combined diphtheria, tetanus, acellular pertussis vaccine

GlaxoSmithKline · FDA-approved active Biologic Quality 5/100

Combined diphtheria, tetanus, acellular pertussis vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently FDA-approved.

At a glance

Generic nameCombined diphtheria, tetanus, acellular pertussis vaccine
SponsorGlaxoSmithKline
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Combined diphtheria, tetanus, acellular pertussis vaccine

What is Combined diphtheria, tetanus, acellular pertussis vaccine?

Combined diphtheria, tetanus, acellular pertussis vaccine is a Biologic drug developed by GlaxoSmithKline.

Who makes Combined diphtheria, tetanus, acellular pertussis vaccine?

Combined diphtheria, tetanus, acellular pertussis vaccine is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is Combined diphtheria, tetanus, acellular pertussis vaccine in?

Combined diphtheria, tetanus, acellular pertussis vaccine is FDA-approved (marketed).

Related